MAPT and Alzheimer disease: We previously showed that a well-known antibiotic, rifampicin, inhibits the oligomer formation of Aβ, tau, and α-synuclein in vitro, and when administered orally or intranasally improves cognition by reducing those amyloidogenic protein oligomers in the brains of mouse models of AD, FTLD-tau, and dementia with Lewy bodies, respectively [19,20,21].